3S Bio raises a healthy $711m via HK IPO

The mainland Chinese biotech firm generated strong demand, with the retail tranche of the offering on the Hong Kong bourse 200-times oversubscribed.

3S Bio raises a healthy $711m via HK IPO

Biotech company 3S Bio raised $711 million in a Hong Kong initial public offering on Friday after pricing shares at the top of the range.

The company, which produces drugs to treat bleeding disorders, will use the proceeds from the flotation to fund acquisitions and boost its staff to grab a larger share of China’s drug market.

In total, 3S Bio and Citic’s private equity unit sold 606.1 million shares at HK...

FinanceAsia has updated its subscription model. Registered readers now have the opportunity to read five articles from our award-winning website for free. Please subscribe for unlimited access.

Click for more on: 3s bio | goldman sachs | morgan stanley | citic | pharma

Print Edition

FinanceAsia Print Edition